MorphoSys: EU Conditionally Approves Minjuvi - Lenalidomide To Treat Relapsed Or Refractory DLBCL

MARTINSRIED (dpa-AFX) - The European Commission has granted conditional marketing authorization for Minjuvi or tafasitamab in combination with lenalidomide, followed by Minjuvi monotherapy, for

Related Keywords

Martinsried ,Bayern ,Germany ,United States , ,European Commission ,Morphosys ,Nconditionally ,Pproves ,Injuvi ,Lenalidomide ,Treat ,Relapsed ,Refractory ,Dlbcl ,